Three weekly cisplatin with concurrent radiotherapy is the standard of care in locally advanced head and neck squamous cell carcinoma.(LAHNSCC). This regime increases morbidity and mortality with treatment interruptions in the community setting.
To assess an alternate regime with weekly cisplatin along with concurrent radiotherapy in LAHNSCC.
Settings and Design:
Single centre retrospective study
Methods and Material:
85 patients with LAHNSCC who were treated at our institution from March 2014 to Dec 2017 were analyzed. Weekly cisplatin (30 mg/m2) was given on weeks 1-6 with radiotherapy of 66 Gy delivered in 33 fractions over 6 weeks by using Telecobalt machine.
Statistical analysis used:
Data on the site of the disease, TNM staging, total dose of Radiotherapy, no of chemotherapy cycles were analyzed. The primary endpoint was treatment compliance. Secondary end points were acute toxicities and immediate response to the treatment.
96% of the patients received planned doses of radiotherapy and 72% of the patients were able to complete the radiotherapy treatment within the stipulated period of 60 days. 78% of the patients received 5 or more than 5 cycles of chemotherapy. Overall complete response and partial response was observed in 73 % & 27% of the patients respectively. The incidence of grade 2 and 3 toxicity was recorded in 55 % with this regime.